June 22, 2017 09:17 AM EDT

UK regulators green-light early access to Santhera’s Raxone for Duchenne MD

John Carroll

Editor & Founder

Santhera Pharmaceuticals saw its shares {SIX: $SANN} jump 16% today after the Swiss biotech reported that UK regulators will provide early access to their drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

UK regulators green-light early access to Santhera’s Raxone for Duchenne MD

John Carroll

Editor & Founder

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Summit’s disappointing survival readout raises stakes for full data

Summit says bispecific misses overall survival in closely-watched lung cancer study

Another Bristol Myers exec goes to Acadia; David Southwell takes CEO job at ARCH-backed cancer biotech

As a challenging first half nears a close, biopharma uncertainty persists

Sanofi, Regeneron report underwhelming COPD data for IL-33 antibody, shares drop

From weeks to days: how Aizon Intelligent Agents transform pharma validation

UK reg­u­la­tors green-light ear­ly ac­cess to San­thera’s Rax­one for Duchenne MD

Editor & Founder

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

UK regulators green-light early access to Santhera’s Raxone for Duchenne MD